Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the development and manufacture of ...

Kashiv Biosciences, and Advanz Pharma announced positive topline results from a confirmatory efficacy study comparing AVT23, ...

Kashiv has reported positive topline outcomes from the confirmatory trial of the proposed biosimilar to Novartis’ Xolair, ADL ...

We came across a bullish thesis on Alvotech (ALVO) on M.V Cunha’s Substack. In this article, we will summarize the bulls’ thesis on ALVO. Alvotech (ALVO)’s share was trading at $10.37 as of ...

EMA committee recommends marketing approval of AVT06, Alvotech’s proposed biosimilar to Eylea: Reykjavik, Iceland Tuesday, June 24, 2025, 17:00 Hrs [IST] Alvotech, a global biot ...

Alvotech has developed a biosimilar of Humira called AVT02, the first-filed biosimilar drug equal in strength to Humira’s latest formulation, which AbbVie markets as a high-concentration, pain ...

TevaU and Alvotech claim first US approval for first biosimilar of AbbVie’s high-concentration Humira, which accounts for 88% of brand prescriptions.

Alvotech is just the latest pharma company to spur an Eylea biosimilar into the European market after Bayer’s blockbuster lost regulatory exclusivity in mid-2024. Formycon’s FYB203, known under the ...

In the last week, the United States market has been flat, but it is up 11% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks ...